推薦產品
product name
Foxo1 抑制剂,AS1842856, Foxo1 Inhibitor, AS1842856, is a cell-permeable inhibitor that blocks the transcription activity of Foxo1 (IC₅₀ = 33 nM). Directly binds to the active Foxo1, but not the Ser256-phosphorylated form.
品質等級
化驗
≥98% (HPLC)
形狀
solid
製造商/商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
off-white to tan
tan to yellow
溶解度
DMSO: 5 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
SMILES 字串
O=C1C(C(O)=O)=CN(C2=C1C(N)=C(F)C(NC3CCCCC3)=C2)CC
一般說明
一种细胞可渗透性的氧代二氢喹啉,比功能相关的Foxo3a和Foxo4优先抑制Forkhead box O家族成员Foxo1的转录活性(在基于HepG2的报告基因分析中分别抑制70%,20%和3%;[AS184256]=100 nM),通过直接结合非Ser256磷酸化/活性Foxo1,而不是Ser256磷酸化/非活性形式的Foxo1以剂量依赖性方式(IC50=33 nM)结合。在体内26小时禁食期间,显示可在体外大鼠肝瘤Fao培养物(针对PEPCK和G6Pase mRNA水平,IC50=37和130 nM;针对葡萄糖的产生,IC50 =43 nM)和在正常血糖ICR小鼠(分别抑制肝G6Pase和PEPCK mRNA水平的60%和45%;3个在0、12、24小时的100 mg/kg p.o.剂量)以及糖尿病db/db小鼠的鼠肝中(对肝G6Pase,ABCG8,ABCG5,PEPCK,IL-1β和apoCIII mRNA水平分别为86%,70%,56%,48%,35%和31%;3个在0、12、24小时的100 mg/kg p.o.剂量)抑制糖异生。
一种细胞可渗透性的氧代二氢喹啉,比功能相关的Foxo3a和Foxo4优先抑制Forkhead box O家族成员Foxo1(IC50 = 33 nM)的转录活性(在基于HepG2的报告基因分析中分别抑制70%,20%和3%;[AS184256]=100 nM),通过直接结合活性Foxo1,而不是Ser256磷酸化/非活性形式的Foxo1。显示在体外大鼠肝瘤Fao培养物中抑制糖异生(针对葡萄糖产生的IC50=43 nM),在体内26小时禁食期间(100 mg/kg/8 h p.o.)抑制非糖尿病和糖尿病的小鼠肝脏中的糖异生。也可以50 mM的DMSO溶液(货号506081)提供。
包裝
用惰性气体包装
警告
毒性:监管审查(Z)
重構
复溶后,等分并冷冻保存(-20°C)。储备溶液在-20°C下可稳定保存至多3个月。
其他說明
Nagashima, T., et al. 2010.Mol.Pharmacol.78, 961.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 1
閃點(°F)
Not applicable
閃點(°C)
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。
Science advances, 7(51), eabg6856-eabg6856 (2021-12-16)
Circadian rhythm disruption (CD) is associated with impaired glucose homeostasis and type 2 diabetes mellitus (T2DM). While the link between CD and T2DM remains unclear, there is accumulating evidence that disruption of fasting/feeding cycles mediates metabolic dysfunction. Here, we used
The Journal of experimental medicine, 219(11) (2022-09-07)
Human adaptive-like natural killer (NK) cells express low levels of FcεRIγ (FcRγ-/low) and are reported to accumulate during COVID-19 infection; however, the mechanism underlying and regulating FcRγ expression in NK cells has yet to be fully defined. We observed lower
Nature communications, 13(1), 4352-4352 (2022-07-28)
Obesity is a pre-disposing condition for chronic obstructive pulmonary disease, asthma, and pulmonary arterial hypertension. Accumulating evidence suggests that metabolic influences during development can determine chronic lung diseases (CLD). We demonstrate that maternal obesity causes early metabolic disorder in the
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務